ოთხშაბათი, აპრილი 15, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Specialty

Calcium Caseinate

Also known as: Casein calcium salt, Calcium casein

LOW RISK 1.0/10 How?

This ingredient is classified as unclassified risk.

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Calcium caseinate is the calcium salt form of casein protein. It is a slow-digesting complete protein with a high biological value. Very well tolerated. Avoid in milk protein allergy. Provides a significant calcium contribution at high doses.

Classification

Biological and Chemical Classification

Information not yet available for this ingredient profile.

Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Specialty
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Specialty
Ingredient Calcium Caseinate
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Specialty
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Calcium Caseinate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Calcium Caseinate
Evidence reviewed 10 peer-reviewed studies (last 10 years)
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 06 აპრ 2026, 12:12

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Influence of Alternative Protein Sources on the Physicochemical Properties and Sensory Evaluation of a Buffalo Whey-Based Cocoa Beverage. ↗
    Journal J Food Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Rekowsky BSDS et al.. Influence of Alternative Protein Sources on the Physicochemical Properties and Sensory Evaluation of a Buffalo Whey-Based Cocoa Beverage.. J Food Sci. 2026. PMID:41906441.
  2. Observational / other LOW evidence YELLOW
    The effects of pasteurization on caseinate-based edible film solutions. ↗
    Journal J Dairy Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    McAnulty MJ et al.. The effects of pasteurization on caseinate-based edible film solutions.. J Dairy Sci. 2026. PMID:41780864.
  3. Observational / other LOW evidence YELLOW
    Co-gels of milk proteins and oat starch: A rheological, textural and microstructural perspective. ↗
    Journal Int J Biol Macromol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Kumar L et al.. Co-gels of milk proteins and oat starch: A rheological, textural and microstructural perspective.. Int J Biol Macromol. 2026. PMID:41558562.
  4. Observational / other LOW evidence YELLOW
    The addition of plant protein to yogurt reduces the bioaccessibility of essential elements. ↗
    Journal Food Res Int
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Costa-Santos AC et al.. The addition of plant protein to yogurt reduces the bioaccessibility of essential elements.. Food Res Int. 2025. PMID:41267294.
  5. Observational / other LOW evidence YELLOW
    Exploring Biodegradable Polymeric Nanocomposite Films for Sustainable Food Packaging Application. ↗
    Journal Polymers (Basel)
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Gomez Mesa NE et al.. Exploring Biodegradable Polymeric Nanocomposite Films for Sustainable Food Packaging Application.. Polymers (Basel). 2025. PMID:40871155.
  6. Observational / other LOW evidence YELLOW
    Caseinate-Carboxymethyl Chitosan Composite Edible Coating with Soybean Oil for Extending the Shelf Life of Blueberry Fruit. ↗
    Journal Foods
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Mohamed AMA et al.. Caseinate-Carboxymethyl Chitosan Composite Edible Coating with Soybean Oil for Extending the Shelf Life of Blueberry Fruit.. Foods. 2025. PMID:40807536.
  7. Observational / other LOW evidence YELLOW
    Effects of Zinc-Layered Filler Incorporation Routes on the Antimicrobial, Mechanical, and Physical Properties of Calcium Caseinate Biopolymeric Films. ↗
    Journal Molecules
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Becerra ME et al.. Effects of Zinc-Layered Filler Incorporation Routes on the Antimicrobial, Mechanical, and Physical Properties of Calcium Caseinate Biopolymeric Films.. Molecules. 2025. PMID:40807484.
  8. Observational / other LOW evidence YELLOW
    Holographic sensor for the rapid detection ofu00a0milku00a0adulteration. ↗
    Journal Appl Opt
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Zhang Y et al.. Holographic sensor for the rapid detection ofu00a0milku00a0adulteration.. Appl Opt. 2025. PMID:40793746.
  9. Observational / other LOW evidence YELLOW
    Blackseed Oil Supplemented Caseinate-Carboxymethyl Chitosan Film Membrane for Improving Shelf Life of Grape Tomato. ↗
    Journal Materials (Basel)
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Mohamed AMA et al.. Blackseed Oil Supplemented Caseinate-Carboxymethyl Chitosan Film Membrane for Improving Shelf Life of Grape Tomato.. Materials (Basel). 2025. PMID:40508649.
  10. Observational / other LOW evidence YELLOW
    The impact of sex and the cheese matrix on cholesterol metabolism in middle-aged adults. ↗
    Journal Atherosclerosis
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    Rooney M et al.. The impact of sex and the cheese matrix on cholesterol metabolism in middle-aged adults.. Atherosclerosis. 2025. PMID:39923541.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 1.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 1.0 / 10

Final GIRI Score for Calcium Caseinate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 1.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
1.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Calcium Caseinate

GIRI Score 1.0 / 10

A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.